Lexaria Bioscience Announces Reverse Stock Split to Regain Nasdaq Compliance
Lexaria Bioscience announces a 1-for-15 reverse stock split effective August 3, 2026, to regain Nasdaq compliance and stabilize its stock price, leveraging its DehydraTECH drug delivery platform.
This reverse stock split is critical for Lexaria's continued Nasdaq listing, which directly impacts its ability to attract partners and investors, and ultimately the commercialization of its DehydraTECH drug delivery technology. For shareholders, it aims to stabilize the stock price and prevent delisting, preserving their investment and the company's access to capital markets.
